Status:
UNKNOWN
The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
Lead Sponsor:
Samsung Medical Center
Conditions:
Chronic Kidney Disease
Proteinuria
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent p...
Eligibility Criteria
Inclusion
- Chronic kidney disease patients with
- proteinuria of 1 - 10 g/day,
- stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),
- stable renal function with GFR ≥ 30 mL/min/ m2,
- diabetes or non-diabetes
Exclusion
- Uncontrolled diabetes (defined as HbA1c \> 9.0%)
- Immunosuppressive treatment within 6 months
- Intractable edema
- Hyperkalemia (\>5.5 mEq/L) or Hypokalemia (\< 3.5 mEq/L)
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00858299
Start Date
March 1 2009
End Date
December 1 2011
Last Update
March 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Nephrology, Samsung Medical Center
Seoul, Seoul, South Korea, 135-710